Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
March 18, 2024 15:41 ET | Orchard Therapeutics (Europe) Limited
TOKYO and LONDON and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
February 05, 2024 07:00 ET | Orchard Therapeutics (Europe) Limited
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells ...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
February 02, 2024 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
January 25, 2024 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on...
Orchard-New-Logo-102419-v01-rgb.png
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
January 24, 2024 05:00 ET | Orchard Therapeutics (Europe) Limited
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
December 11, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
November 30, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
November 13, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
October 26, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a range of interim clinical outcomes, in addition to the...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
October 24, 2023 07:00 ET | Orchard Therapeutics (Europe) Limited
Eight presentations highlight the differentiated profile and broad applicability of the company’s HSC gene therapy platform Data from proof-of-concept study of OTL-203 in MPS-IH demonstrate...